About the Meeting

The 3rd Joint ASTCT + EBMT Basic and Translational Scientific Meeting is a 2.5-day conference focused on cutting-edge basic and translational biology in the field. The meeting will focus on fundamental themes and novel technologies with an emphasis on unpublished and innovative science. Attendance to the meeting will be limited to 100 attendees with afternoon breaks to allow for informal networking opportunities between junior and senior attendees. The meeting will host two days of poster sessions and a best oral abstract session.

Who Should Attend

  • Advanced Practice Providers
  • Hematopathologists
  • Medical and Pediatric Hematologists and Oncologists
  • Oncology Nurses
  • Pharmacists
  • Physicians In Training
  • Translational and Basic Scientists
  • Other Associated Allied Health Professionals

Registration

Registration Rates
Type Price
Standard Registration $400
Trainee & Junior Faculty* $275
Allied Health Professionals $275

Register

*Junior attendees are defined as post doctoral fellows, current fellows, and junior faculty within the first three years of appointment.

Registration to this event is limited to a maximum of 100 total attendees. We are unable to accept additional registrants once the registration capacity has been met.

This conference is only for physicians and scientists who are currently practicing in the field of transplantation and cellular therapy and sponsoring companies. Please contact Angie Dahl (adahl@astct.org) if you are interested in participating as a sponsor.

Agenda

Day 1: Wednesday, May 15
Topic: Chronic Graft vs Host Disease | Session Chair: Bruce Blazar, MD; University of Minnesota
8:00 – 8:15 AM
(15 mins)
Welcome and Introduction
8:15 – 8:45 AM
(30 mins)
Distinct Brain Chronic GVHD Pathophysiology Highlights the Need for Organ Specific Targeted Therapeutics

Kelli MacDonald, PhD; QIMR Berghofer Medical Research Institute, AU
8:45 – 9:15 AM Chronic GVHD; Current Challenges in Translating our Pathophysiology Knowledge into Clinical Practice

Gerard Socie, MD, PhD; Hopital Saint-Louis; FR
9:15 – 9:45 AM
(15 mins)
Targeting Pathways that Drive B Cell Fate and Function after HCT

Stefanie Sarantopoulos, MD, PhD; Duke University, US
9:45 – 10:00 AM
(15 mins)
Abstract 1: Absence of MHC Class I Expression on Target Cells Exacerbates CD4+ T Cell Mediated Killing

Emma Lauder, BA; University of Michigan, US
10:00 – 10:30 AM
(30 mins)
Break
Topic: Genome Editing | Session Chair: Chiara Bonini, MD; IRCCS Ospedale San Raffaele
10:30 – 11:00 AM
(30 mins)
TCR and Inhibitory Receptor Gene Editing for Cancer Immunotherapy

Chiara Bonini, MD; IRCCS Ospedale San Raffaele, IT
11:00 – 11:30 AM
(30 mins)
Advanced TCR Engineering for Repertoire Analysis and Adoptive T Cell Therapy

Dirk Busch, MD; Technische Universität München, DE
11:30 – 12:00 PM
(30 mins)
Base Edited CAR T Cells for Acute Leukemia

Waseem Qasim, MD; University College London, UK

12:00 - 12:15 PM

(15 mins)

Abstract 2: Cytosine Base Editor Ameliorates the Safety Profile of TCR Edited T Cells for the Adoptive Cell Therapy of Gastrointestinal Tumors

Martina Spiga, PhD; San Raffaele Scientific Institute, IT
12:15 – 5:00 PM Lunch and Afternoon Networking
5:00 – 6:00 PM Poster Tour and Networking Hour
6:00 – 7:30 PM Allogeneic Hematopoietic Cell Transplantation in Seattle as an Example of Intensive Bench-to-Bedside Research

Rainer Storb, MD; Fred Hutchinson Cancer Center, US
Day 2: Thursday, May 16
Topic: Cell Engineering | Session Chair: Carl June, MD; University of Pennslyvania
8:00 – 8:30 AM
(30 mins)
Applying Genome Engineering to Enhance CAR T cells

Carl June, MD; University of Pennsylvania, US
8:30 – 9:00 AM
(30 mins)
Novel Ways to Metabolically Rewire T Cells for Adoptive Immunotherapy

Chrystal Paulos, PhD; Winship Cancer Institute, US
9:00 – 9:30 AM
(30 mins)
Advancing Novel Cellular Immunotherapies for Solid Tumors: Clinical Trials and Tribulations, and a Bright Future

Saul J. Priceman, PhD; City of Hope, US
9:30 – 9:45 AM
(15 mins)
Abstract 3: Human OX40l-Car-Tregs Target Activated Antigen-Presenting Cells and Effectively Control T Cell Alloreactivity, PhD

Xianliang Rui PhD; Boston Children’s Hospital, US
9:45 – 10:15 AM
(30 mins)
Break
Topic: Malignant and Non-malignant Hematopoiesis | Session Chair: Pavan Reddy, MD; Baylor College of Medicine
10:15 – 10:45 AM
(30 mins)
Epigenetic Regulators in Clonal Hematopoiesis

Margaret (Peggy) Goodell, PhD; Baylor College of Medicine, US
10:45 – 11:15 AM
(30 mins)
Decoding Human Hematopoietic Stem Cell Self-Renewal

Hanna Mikkola, MD, PhD; University of California Los Angeles, US
11:15 – 11:45 PM
(30 mins)
Regulation of Hematopoietic Stem Cell Dormancy

Nina Cabezas Wallscheid, PhD; Max-Planck-Institute of Immunobiology and Epigenetics, DE
11:45 AM – 12:00 PM
(15 mins)
Abstract 4: Combined TCR-Seq and Multiparameter Flow Cytometry Reveal a T-Cell Bottleneck and Delayed Tnaive Reconstitution After Post-Transplant Cyclophosphamide With Implications for Efficacy and Toxicity: Results of the BMT-CTN 1801 Study

Susan Ehrenkranz De Wolf, MD; Memorial Sloan Kettering Cancer Center
12:00 – 5:00 PM Lunch and Afternoon Networking
5:00 – 6:00 PM Meet the Professor Session
6:00 – 7:30 PM HLA in Cellular Therapy: Past, Present and Future

Katharina Fleischhauer, MD; Institute for Experimental Cellular Therapy/University Hospital Essen, DE
Day 3: Friday, May 17
Topic: Biology of Relapse | Session Chair: Nicolaus Kroger, MD; University Hospital Hamburg-Eppendorf, DE
8:00 – 8:30 AM
(30 mins)
Toward the Development of Synthetic Immunity to Cancer

Kole Roybal, PhD; University of California, San Francisco, US
8:30 – 9:00 AM
(30 mins)
Using Marrow Infiltrating T Cells to Treat Relapse Post HSCT With PTCy

Leonido Luznik, MD; Johns Hopkins University, US
9:00 – 9:30 AM
(30 mins)
Azacytidine and AML: It All Goes Back to Globin

Timothy Ley, MD; Washington University School of Medicine, US
9:30 – 9:45 AM
(15 mins)
Abstract 5: Terminally Exhausted CD8 T Cells Maintain Functional Capacity After Stem Cell Transplantation or CAR T Cell Therapy for Hematological Malignancies

Simone Minnie, PhD; Fred Hutchinson Cancer Center, US
9:45 – 10:00 AM
(30 mins)
Closing Remarks

Housing

Hilton Washington D.C. National Mall the Wharf

480 L’Enfant Plaza SW
Washington D.C. 20024

(202) 484-1000

Registered attendees will receive the housing link to secure discounted room rates in their official registration confirmation email.

Room Rate

$329.00 plus tax per night (single/double). The room rate will increase by $20 per night for additional people.

Housing Rate Cutoff

To take advantage of the discounted room rate, be sure to book your reservation on or before April 24, 2024. After April 24, the room block will be released and the negotiated room rates may not be available. Please make sure the hotel is aware of any special needs. They will assign specific room types and any other requests based on availability.

Deposits

Please have your credit card information on hand upon booking your reservation. The Hilton Washington D.C. National Mall the Wharf requires each individual reservation be guaranteed with a deposit equal to one night’s room and tax.

Changes or Cancellations

The Hilton Washington D.C. National Mall the Wharf requires that you cancel your reservation (72) hours prior to your arrival. The deposit of one night’s room and tax will be forfeited for cancellations made less than (72) hours from arrival. Please call the hotel directly to make a cancellation and keep your cancellation confirmation number for your records. Name changes can be made to reservations any time prior to check-in, without incurring a fee.

Confirmations

The hotel will send you a confirmation to the email used in booking your reservation using the customized online reservation link provided by ASTCT-EBMT. Review it carefully for accuracy and keep a copy for your records.

Nearby Things To Do

Discover the best things to do in Washington D.C., from events happening right now to annual festivals and so much more.